{"entity":{"id":"bcg-unresponsive","kind":"term","name":"BCG-unresponsive","aka":[],"tldr":"The FDA's definition of early bladder cancer that has failed adequate BCG treatment, the population in which most new bladder drugs are first approved.","summary":"Persistent or recurrent CIS within 12 months of adequate BCG (at least 5 of 6 induction and 2 of 3 maintenance doses), or high-grade Ta/T1 recurrence within 6 months, or T1 high-grade at first evaluation after induction. Historically treated with radical cystectomy; now pembrolizumab, nadofaragene, N-803 + BCG, TAR-200, and (filing) cretostimogene offer bladder-sparing options with CR rates of 40-80%.","asOf":"2026-09-07","links":[{"label":"EAU guidelines: non-muscle-invasive bladder cancer","url":"https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer"}],"tags":[],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["tar-200","cretostimogene","nogapendekin-alfa","nadofaragene-firadenovec"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Clinical","wikipediaChecked":"2026-09-22"},"route":"/terms/bcg-unresponsive/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"drug":[{"id":"cretostimogene","kind":"drug","name":"Cretostimogene grenadenorepvec","route":"/drugs/cretostimogene/"},{"id":"tar-200","kind":"drug","name":"Gemcitabine intravesical system (TAR-200)","route":"/drugs/tar-200/"},{"id":"bcg-intravesical","kind":"drug","name":"Intravesical BCG","route":"/drugs/bcg-intravesical/"},{"id":"nadofaragene-firadenovec","kind":"drug","name":"Nadofaragene firadenovec","route":"/drugs/nadofaragene-firadenovec/"},{"id":"nogapendekin-alfa","kind":"drug","name":"Nogapendekin alfa inbakicept","route":"/drugs/nogapendekin-alfa/"}],"trial":[{"id":"bond-003","kind":"trial","name":"BOND-003","route":"/trials/bond-003/"},{"id":"quilt-3-032","kind":"trial","name":"QUILT 3.032","route":"/trials/quilt-3-032/"},{"id":"sunrise-1","kind":"trial","name":"SunRISe-1","route":"/trials/sunrise-1/"}],"technology":[{"id":"bcg-and-intravesical-therapy","kind":"technology","name":"Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)","route":"/technologies/bcg-and-intravesical-therapy/"}],"bottleneck":[{"id":"b-resistance","kind":"bottleneck","name":"Acquired resistance to every therapy","route":"/bottlenecks/b-resistance/"}],"pathway":[{"id":"nk-cell-recognition","kind":"pathway","name":"NK-cell recognition: missing self & stress ligands","route":"/pathways/nk-cell-recognition/"}]}}